Fernando Cássio Do Prado Silva

Fernando Cássio Do Prado Silva

Auto-generated profile, based on publicly available information

Fernando Cássio Do Prado Silva


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 August 2024 in Hearts
Verified
Journal Article
Open access
PDF file
RFRostand Moreira Fernandes
Rostand Moreira Fernandes
JPJoão Paulo Jordão Pontes
João Paulo Jordão Pontes
CBCelso Eduardo Rezende Borges
Celso Eduardo Rezende Borges
DNDemócrito Ribeiro de Brito Neto
Demócrito Ribeiro de Brito Neto
APAnastácio de Jesus Pereira
Anastácio de Jesus Pereira
FSFernando Cássio Do Prado Silva
Fernando Cássio Do Prado Silva
In cardiac surgery, poststernotomy pain is a significant issue, peaking within 48 h and requiring proper analgesia for both acute relief and avoidance of chronicization. Opioids are commonly used for pain management postsurgery but pose risks such as adverse effects and dependency. Post-cardiac surgery pain can stem from various sources—somatic, visceral, and neuropathic—making opioid reliance a concern. Multimodal analgesia, which combines different medications and regional anesthesia techniques, is increasingly recommended to decrease opioid use and its related problems. Strategies include acetaminophen, gabapentinoids, NMDA antagonists, alpha-2 agonists, intravenous lidocaine, anti-inflammatory drugs, and regional anesthesia. These approaches can enhance pain control, reduce opioid reliance, and improve cardiac surgery outcomes. The ERAS® Cardiac Society strongly advocates for an opioid-sparing multimodal approach to improve patient recovery by reducing complications and increasing patient satisfaction. This review aims to consolidate current evidence to assist healthcare providers in customizing pain management for patients post-cardiac surgery, emphasizing reduced opioid use and optimizing the recovery process.

23 February 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
JPJoão Paulo Jordão Pontes
João Paulo Jordão Pontes
IRIsabella Rodrigues Reis
Isabella Rodrigues Reis
APAnastácio de Jesus Pereira
Anastácio de Jesus Pereira
NPNeise Apoliany Martins Pacheco
Neise Apoliany Martins Pacheco
CBCelso Eduardo Rezende Borges
Celso Eduardo Rezende Borges
FSFernando Cássio Do Prado Silva
Fernando Cássio Do Prado Silva
Background/Objectives: Intraoperative methadone has emerged as a significant pharmacological strategy in cardiac surgery to improve postoperative analgesic outcomes and reduce the reliance on rescue short action opioids. This review aims to synthesize evidence regarding the safety and efficacy of intravenous methadone compared to other strategies for postoperative pain control in adult and pediatric cardiac surgeries. Methods: This scoping review relied on electronic searches in PubMed, Web of Science, Cochrane Library, and EMBASE up to January 2026. From 199 articles retrieved, 41 were included, focusing on analgesic efficacy, safety, pharmacokinetic variations during cardiopulmonary bypass (CPB), and cost-effectiveness. Results: The implementation of methadone results in a 30% to 70% reduction in postoperative opioid requirements. Patients experience significantly lower pain scores from 24 to 72 hours and a 20% to 30% improvement in satisfaction regarding their recovery. In pediatric populations (neonates and children), the use of methadone leads to a significant reduction in opioid needs and a high rate of extubation in the operating room. Pharmacokinetically, a 48% drop in methadone concentration occurs during CPB due to hemodilution and sequestration. Safety data confirms that intraoperative use does not prolong mechanical ventilation; however, doses exceeding 0.25 mg/kg are linked to an increased incidence of delirium. Economically, optimized recovery generates savings of up to $6,355 per patient within seven days. Conclusions: Intraoperative methadone is a robust and safe analgesic option for cardiac surgery, including pediatric cases. It offers profound opioid-sparing effects and significant cost reductions, if dosages are carefully managed to minimize delirium risks.

6 May 2026 in Hearts
Verified
Journal Article
Open access
PDF file
JPJoão Paulo Jordão Pontes
João Paulo Jordão Pontes
IRIsabella Rodrigues Reis
Isabella Rodrigues Reis
APAnastácio de Jesus Pereira
Anastácio de Jesus Pereira
NPNeise Apoliany Martins Pacheco
Neise Apoliany Martins Pacheco
CBCelso Eduardo Rezende Borges
Celso Eduardo Rezende Borges
FSFernando Cássio Do Prado Silva
Fernando Cássio Do Prado Silva
Background/Objectives: Intraoperative methadone has emerged as a significant pharmacological strategy in cardiac surgery to improve postoperative analgesic outcomes and reduce the reliance on rescue short-action opioids. This review aims to synthesize evidence regarding the safety and efficacy of intravenous methadone compared to other strategies for postoperative pain control in adult and pediatric cardiac surgeries. Methods: This narrative review relied on electronic searches in PubMed, Web of Science, Cochrane Library, and EMBASE up to January 2026. From 199 articles retrieved, 41 were included, focusing on analgesic efficacy, safety, pharmacokinetic variations during cardiopulmonary bypass (CPB), and cost-effectiveness. Results: The implementation of methadone results in up to 70% reduction in postoperative opioid requirements. Patients experience significantly lower pain scores from 24 to 72 h and improvement in satisfaction regarding pain management. In pediatric populations (neonates and children), the use of methadone leads to a significant reduction in opioid needs and a high rate of extubation in the operating room. Pharmacokinetically, a 48% drop in methadone concentration occurs during CPB due to hemodilution and sequestration. Safety data confirms that intraoperative use does not prolong mechanical ventilation; however, doses exceeding 0.25 mg/kg are linked to an increased incidence of delirium. Economically, methadone can be cost-effective, resulting in savings of up to $6355 per patient. Conclusions: Intraoperative methadone improves postoperative analgesia, opioid consumption, patient satisfaction, and costs after cardiac surgery. Its opioid-sparing effects make it particularly attractive for ERAS protocols, although vigilance against dose-related delirium and QT prolongation remains essential. Further research, especially in pediatrics, is needed to refine dosages and safety protocols.

1 August 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
RFRostand Moreira Fernandes
Rostand Moreira Fernandes
JPJoão Paulo Jordão Pontes
João Paulo Jordão Pontes
CBCelso Eduardo Rezende Borges
Celso Eduardo Rezende Borges
DNDemócrito Ribeiro de Brito Neto
Demócrito Ribeiro de Brito Neto
APAnastácio de Jesus Pereira
Anastácio de Jesus Pereira
FSFernando Cássio Prado Silva
Fernando Cássio Prado Silva
In cardiac surgery, post-sternotomy pain is a significant issue, peaking within 48 hours and requiring proper analgesia for both acute relief and to avoid chronicization. Opioids are commonly used for pain management post-surgery but pose risks like adverse effects and dependency. Post-cardiac surgery pain can stem from various sources - somatic, visceral, and neuropathic, making opioid reliance a concern. Multimodal analgesia, combining different medications and regional anesthesia techniques, is increasingly recommended to decrease opioid use and its related problems. Strategies include acetaminophen, gabapentinoids, NMDA antagonists, alpha-2 agonists, intravenous lidocaine, anti-inflammatory drugs, and regional anesthesia. Implementing these approaches can enhance pain control, lessen opioid reliance, and improve cardiac surgery outcomes. The ERAS® Cardiac Society strongly advocates for an opioid-sparing multimodal approach to benefit patient recovery by reducing complications and enhancing satisfaction. This review aims to consolidate current evidence to assist healthcare providers in customizing pain management for patients post-cardiac surgery, emphasizing reduced opioid use and optimizing the recovery process.